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Abstract: Multi-arm designs provide an effective means of evaluating several treatments
within the same clinical trial. Given the large number of treatments now available for
testing in many disease areas, it has been argued that their utilisation should increase.
However, for any given clinical trial there are numerous possible multi-arm designs that
could be used, and choosing between them can be a difficult task. This task is compli-
cated further by a lack of available easy-to-use software for designing multi-arm trials.
To aid the wider implementation of multi-arm clinical trial designs, we have developed
a web application for sample size calculation when using a variety of popular multiple
comparison corrections. Furthermore, the application supports sample size calculation
to control several varieties of power, as well as the determination of optimised arm-wise
allocation ratios. It is built using the Shiny package in the R programming language,
is free to access on any device with an internet browser, and requires no programming
knowledge to use. The application provides the core information required by statisticians
and clinicians to review the operating characteristics of a chosen multi-arm clinical trial
design. We hope that it will assist with the future utilisation of such designs in practice.
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Background
Drug development is becoming an increasingly expensive process, with the estimated
average cost per approved new compound now standing at over $1 bn [1]. In no small
part this is due to the high failure rate of clinical trials, in particular in phases II and
III. This is particularly true in the field of oncology, where the likelihood of approval
from phase I is only 5.1% [2]. Consequently, the clinical research community is constantly
seeking new methods that may improve the efficiency of the drug development process.
One possible method, which has received substantial attention in recent years, is the
idea to make use of multi-arm designs that compare several experimental treatments to
a shared control group. Several desirable, inter-related, features of such designs have
now been described. For example, the number of patients on the control treatment is
typically reduced compared to conducting separate two-arm trials, and simultaneously
patients are more likely to be randomized to an experimental treatment, which may help
with recruitment [3, 4]. Furthermore, the overall required sample size, for the same level
of power, will typically be smaller than that which would be required if multiple two-arm
trials were conducted [5]. Finally, multi-arm designs offer a fair head-to-head comparison
of experimental treatments in the same study [3, 4], and the cost of assessing a treatment
in a multi-arm trial is often around half of that for a separate two-arm trial [3].
Based upon these advantages, and their experiences of utilising such designs in several
oncology trials, Parmar et al. [3] make a compelling case for the need for more multi-arm
designs to be used in clinical research. We are not aware of any systematic evidence on
whether this has now permeated through to practice, but a simple search of PubMed
Central suggests it may be the case: 859 articles have included the phrases “multi-arm”
and “clinical trial” since 2015, as opposed to just 273 in all years prior to this. Considering
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this result in combination with the findings of Baron et al. [6], who determined 17.9% of
trials published in 2009 were multi-arm, as well as the recent publication of a key guidance
document on reporting results from multi-arm trials [7], it is clear that there is now much
interest within the trials community in such designs.
However, whilst there are numerous advantages of multi-arm trials, it is important
to recognise that determining a suitable design for a multi-arm clinical trial can be a
substantially more complex process than for a two-arm trial. In particular, a decision
must be made on how to account for the multiple comparisons that will be made. Indeed,
whether the final analysis should adjust for multiplicity has been a topic of much debate
within the literature. In brief, presented arguments primarily revolve around the fact that
failing to account for multiplicity can substantially increase the probability of committing
a type-I error. Yet, if a series of two-arm trials were conducted, no adjustment would be
made to the significance level used in each trial. For brevity, we will not repeat all further
arguments on this issue here, and instead refer the reader to several key discussions on
multiplicity [5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18].
For the purposes of what follows in this article, the more important consideration is
that when a multiple comparison correction (MCC) is to be used, one of a wide selection
must actually be chosen (see, e.g., [19, 20, 21] for an overview). MCCs vary widely in their
complexity, with Bonferroni’s correction often recommended because of its simplicity [7].
However, other MCCs often perform better in terms of the operating characteristics they
impart, as Bonferroni’s correction is known to be conservative [10, 18, 20, 22]. A recent
review found that amongst those multi-arm trials that did adjust for multiplicity, 50%
used one of the comparatively simple Bonferroni or Dunnett corrections [5]. Thus, there
arguably remains the potential for increased efficiency gains to be made in multi-arm
trials, if more advanced MCCs can be employed.
Furthermore, regardless of whether a MCC is utilised, there are other complications
that must also be addressed in multi-arm trial design, including how to power the trial,
and what the allocation ratio to each experimental arm relative to the control arm will
be. Indeed, power is not a simple quantity in a multi-arm trial, whilst the literature on
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how to choose the allocation ratios in an optimal manner is extensive (see, e.g., [23] for an
overview), and deciding whether to specify allocation ratios absolutely, or whether they
can be optimised to improve trial efficiency may not be an easy decision.
These considerations imply that user-friendly software for designing multi-arm clinical
trials would be a valuable tool in the trials community. It is unfortunate therefore that
little software is available to assist with such studies. The principal exception to this
is the MULTIARM module for East [24], which allows users to compare the operating
characteristics of many multi-arm designs with respect to numerous important quantities.
However, the cost of this package may be prohibitive to many working within academia.
For this reason, we have developed a web application for multi-arm clinical trial design.
We hope that the availability of this application will assist with the utilization of more
advanced multi-arm designs in future clinical trials.
Implementation
The web application is written using the Shiny package [25] in the R programming lan-
guage [26]. It is available as a function in (for off-line local use), and is built using other
functions from, the R package multiarm [27]. A vignette is provided for multiarm that
gives great detail on its formal statistical specifications. A less technical summary is
provided here.
Design setting
It is assumed that outcomes Xik will be accrued from patients i ∈ {1, . . . , nk} on treatment
arms k ∈ {0, . . . , K}, with arm k = 0 corresponding to a shared control arm, and arms
k ∈ {1, . . . , K} to several experimental arms. Later, we provide more information on
the precise types of outcome that are currently supported by the web application. The
hypotheses of interest are assumed to be Hk : τk ≤ 0 for k ∈ {1, . . . , K}. Here, τk
corresponds to a treatment effect for experimental arm k ∈ {1, . . . , K} relative to the
control arm. Thus, we assume one-sided tests for superiority. Note that in the app,
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reference is also made to the global null hypothesis, HG, which we define to be the
scenario with τ1 = · · · = τK = 0.
To test hypothesis Hk, we assume that a Wald test statistic, zk, is computed
zk =
τˆk√
Var(τˆk)
= τˆkI
1/2
k , k ∈ {1, . . . , K}.
In what follows, we use the notation zk = (z1, . . . , zk)
> ∈ Rk. With this, note that our
app supports design in particular scenarios where Zk, the random pre-trial value of zk,
has (at least asymptotically) a k-dimensional multivariate normal (MVN) distribution,
with
E(Zl) = τlI1/2l , l = 1, . . . , k,
Cov(Zl, Zl) = 1, l ∈ {1, . . . , k},
Cov(Zl1 , Zl2) = I
1/2
l1
I
1/2
l2
Cov(τl1 , τl2), l1 6= l2, l1, l2 ∈ {1, . . . , k}.
As is discussed further later, this includes normally distributed outcome variable scenarios
and, for large sample sizes, other parametric distributions such as Bernoulli outcome data.
Ultimately, to test the hypotheses, zK is converted to a vector of p-values, p =
(p1, . . . , pK)
> ∈ [0, 1]K , via pk = 1 − Φ1(zk, 0, 1), for k ∈ {1, . . . , K}. Here,
Φn{(a1, . . . , an)>,λ,Σ} is the cumulative distribution function of an n-dimensional MVN
distribution, with mean λ and covariance matrix Σ. Precisely
Φn{(a1, . . . , an)>,λ,Σ} =
∫ a1
−∞
· · ·
∫ an
−∞
φn{x,λ,Σ}dxn . . . dx1,
where φn{x,λ,Σ} is the probability density function of an n-dimensional MVN distribu-
tion with mean λ and covariance matrix Σ, evaluated at vector x = (x1, . . . , xn)
>.
Then, which null hypotheses are rejected is determined by comparing the pk to a
set of significance thresholds specified based on a chosen MCC, in combination with a
nominated significance level α ∈ (0, 1). Before we describe the currently supported MCCs
however, we will first describe the operating characteristics that are currently evaluated
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by the app.
Operating characteristics
Our app returns a wide selection of statistical operating characteristics that may be of
interest when choosing a multi-arm trial design. Specifically, it can compute the following
quantities for any nominated multi-arm design and true set of treatment effects
• The conjunctive power (Pcon): The probability that all of the null hypotheses are
rejected, irrespective of whether they are true or false.
• The disjunctive power (Pdis): The probability that at least one of the null hypotheses
is rejected, irrespective of whether they are true or false.
• The marginal power for arm k ∈ {1, . . . , K} (Pk): The probability that Hk is
rejected, irrespective of whether it is true or false.
• The per-hypothesis error-rate (PHER): The expected value of the number of type-I
errors divided by the number of hypotheses.
• The a-generalised type-I familywise error-rate (FWERIa): The probability that at
least a ∈ {1, . . . , K} type-I errors are made. Note that FWERI1 is the conventional
familywise error-rate (FWER); the probability of making at least one type-I error.
• The a-generalised type-II familywise error-rate (FWERIIa): The probability that
at least a ∈ {1, . . . , K} type-II errors are made.
• The false discovery rate (FDR): The expected proportion of type-I errors amongst
the rejected hypotheses.
• The false non-discovery rate (FNDR): The expected proportion of type-II errors
amongst the hypotheses that are not rejected.
• The positive false discovery rate (pFDR): The rate that rejections are type-I errors.
• The sensitivity (Sensitivity): The expected proportion of the number of correct
rejections of the hypotheses to the number of false null hypotheses.
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• The specificity (Specificity): The expected proportion of the number of correctly
not rejected hypotheses to the number of true null hypotheses.
Multiple comparison corrections
Per-hypothesis error-rate control
The most simple method for selecting the significance thresholds against which to compare
the pk, is to compare each to the chosen significance level α. That is, to reject Hk for
k ∈ {1, . . . , K} if pk ≤ α. This controls the PHER to α.
A potential problem with this, however, can be that the statistical operating charac-
teristics of the resulting design may not be desirable (e.g., in terms of FWERI1). As
discussed earlier, it is for this reason that we may wish to make use of a MCC. Currently,
the web application supports the use of a variety of such MCCs, which aim to control
either (a) the conventional familywise error-rate, FWERI1 (with these techniques sub-
divided into single-step, step-down, and step-up corrections) or (b) the FDR.
Single-step familywise error-rate control
These MCCs test each of the Hk against a common significance level, γ ∈ (0, 1) say,
rejecting Hk if pk ≤ γ. The currently supported single-step corrections are
• Bonferroni’s correction: This sets γ = α/K [28].
• Sidak’s correction: This sets γ = 1− (1− α)1/K [29].
• Dunnett’s correction: This sets γ = 1−Φ1{zD, 0, 1}, where zD is the solution of the
following equation
α = 1− ΦK{(zD, . . . , zD)>,0K ,Cov(ZK)},
with 0n = (0, . . . , 0)
> ∈ Rn an n-dimensional vector of zeroes [30].
Note that each of the above specify a γ such that the maximum probability of incor-
rectly rejecting at least one of the null hypotheses Hk, k ∈ {1, . . . , K}, over all possible
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values of τ ∈ RK is at most α. This is referred to as strong control of FWERI1.
Step-down familywise error-rate control
Step-down MCCs work by ranking the p-values from smallest to largest. We will refer
to these ranked p-values by p(1), . . . , p(K), with associated hypotheses H(1), . . . , H(K). The
p(k) are compared to a vector of significance levels γ = (γ1, . . . , γK) ∈ (0, 1)K . Precisely,
the maximal index k such that p(k) > γk is identified, and then H(1), . . . , H(k−1) are
rejected and H(k), . . . , H(K) are not rejected. If k = 1 then we do not reject any of the
null hypotheses, and if no such k exists then we reject all of the null hypotheses. The
currently supported step-down corrections are
• Holm-Bonferroni correction: This sets γk = α/(K + 1− k) [31].
• Holm-Sidak correction: This sets γk = 1− (1− α)K+1−k.
• Step-down Dunnett correction: This can only currently be used when the
Cov(Zk1 , Zk2) are equal for all k1 6= k2, k1, k2 ∈ {1, . . . , K}. In this case, it sets
γk = 1− Φ1{zDk, 0, 1}, where zDk is the solution to
α = 1− ΦK+1−k{(zDk, . . . , zDk)>,0K+1−k,Cov(ZK+1−k)}.
Note that both of the above methods provide strong control of FWERI1.
Step-up familywise error-rate control
Step-up MCCs also work by ranking the p-values from smallest to largest, and similarly
utilise a vector of significance levels γ. However, here, the largest k such that p(k) ≤ γk is
identified. Then, the hypotheses H(1), . . . , H(k) are rejected, and H(k+1), . . . , H(K) are not
rejected. Currently, one such correction is supported: Hochberg’s correction [32], which
sets γk = α/(K + 1− k). This method also provides strong control of FWERI1.
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False discovery rate control
It may be of interest to instead control the FDR, which can offer a compromise between
strict FWERI1 control and PHER control, especially when we expect a large proportion
of the experimental treatments to be effective. Currently, two methods that will control
the FDR to at most α over all possible τ ∈ RK are supported. They function in the
same way as the step-up corrections discussed above, with
• Benjamini-Hochberg correction: This sets γk = kα/K [33].
• Benjamini-Yekutieli correction: This sets [34]:
γk =
kα
K
(
1 + 1
2
+ · · ·+ 1
K
) .
Sample size determination
The sample size required by a design to control several types of power to a specified
level 1 − β, under certain specific scenarios, can be computed. Precisely, following for
example [35], values for ‘interesting’ and ‘uninteresting’ treatment effects, δ1 ∈ R+ and
δ0 ∈ (−∞, δ1) respectively, are specified and the following definitions are made
• The global alternative hypothesis, HA, is given by τ1 = · · · = τK = δ1.
• The least favourable configuration for experimental arm k ∈ {1, . . . , K}, LFCk, is
given by τk = δ1, τ1 = · · · = τk−1 = τk+1 = · · · = τK = δ0.
Then, the following types of power can be controlled to level 1− β by design’s deter-
mined using the app
• The conjunctive power under HA.
• The disjunctive power under HA.
• The minimum marginal power under the respective LFCk.
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Allocation ratios
One of the primary goals of the app is to aid the choice of values for n0, . . . , nK . The
app specifically supports the determination of values for these parameters by searching
for a suitable n0 via a one-dimensional root solving algorithm, and then sets nk = rkn0,
rk ∈ (0,∞), for k ∈ {1, . . . , K}. Here, rk is the allocation ratio for experimental arm k
relative to the control arm.
For this reason, the app also allows the allocation ratios to be specified in a variety
of ways: they can be defined explicitly, or alternatively can be determined in an optimal
manner. For this optimality problem, many possible optimality criteria have been defined,
each with their own merits. Therefore, we refer the reader to Atkinson (2007) [23] for
further details of optimal allocation in multi-arm designs. Instead, we simply note that
in the web application, the allocation ratios can currently be determined for three such
criteria
• A-optimality: Minimizes the trace of the inverse of the information matrix of the
design. This results in the minimization of the average variance of the treatment
effect estimates.
• D-optimality: Maximizes the determinant of the information matrix of the design.
This results in the minimization of the volume of the confidence ellipsoid for the
treatment effect estimates.
• E-optimality: Maximizes the minimum eigenvalue of the information matrix. This
results in the minimization of the maximum variance of the treatment effect esti-
mates.
The optimal allocation ratios are identified in the app using available closed-form so-
lutions were possible (see [36] for a summary of these), otherwise non-linear programming
is employed.
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Other design specifications
Finally, the web application also supports the following options
• Plot production: Plots can be produced of (a) all of the operating characteristics
quantities listed earlier when τ1 = · · · = τK = θ, as well as (b) the Pk when τk = θ
and τl = θ − (δ1 − δ0) for l 6= k. If these are selected for rendering, the quality of
the plots, in terms of the number of values of θ used for line-graph production, can
also be controlled.
• Require nk ∈ N for k ∈ {0, . . . , K}: By default, the sample size determined for each
arm will only be required to be a positive number. In practice, such values need to
be integers. This can thus be enforced if desired, with the integer nk specified by
rounding up their determined continuous values.
Supported outcome variables
Normally distributed outcome variables
Currently, the app supports multi-arm trial design for scenarios in which the outcome
variables are assumed to be either normally or Bernoulli distributed.
Precisely, for the normal case, it assumes that Xik ∼ N(µk, σ2k), and that σ2k is known
for k ∈ {0, . . . , K}. Then, for each k ∈ {1, . . . , K}
τk = µk − µ0,
τˆk =
1
nk
nk∑
l=1
xik − 1
n0
n0∑
l=1
xi0,
Ik =
1
σ20
n0
+
σ2k
nk
,
where xik is the realised value of Xik.
Note that in this case, ZK has a MVN distribution, and thus the operating character-
istics can be computed exactly and efficiently using MVN integration [37]. Furthermore,
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the distribution of ZK does not depend upon the values of the µk, k ∈ {0, . . . , K}.
Consequently, these parameters play no part in the inputs or outputs of the app.
Bernoulli distributed outcome variables
In this case, Xik ∼ Bern(pik) for response rates pik, and for each k ∈ {1, . . . , K}
τk = pik − pi0,
τˆk =
1
nk
nk∑
l=1
xik − 1
n0
n0∑
l=1
xi0,
Ik =
1
pi0(1−pi0)
n0
+ pik(1−pik)
nk
.
Thus, a problem for design determination becomes that the Ik are dependent on the
unknown response rates. In practice, this is handled at the analysis stage of a trial by
setting
Ik =
1
pˆi0(1−pˆi0)
n0
+ pˆik(1−pˆik)
nk
,
for pˆik =
∑nk
l=1 xik/nk, k ∈ {0, . . . , K}. This is the assumption made where required
in by the app. With this, ZK is only asymptotically MVN. Thus, in general it would
be important to validate operating characteristics evaluated using MVN integration via
simulation.
In addition, note that the above problem also means that the operating characterstics
under HG, HA, and the LFCk are not unique without further restriction. Thus, to achieve
uniqueness, the app requires a value be specified for pi0 for use in the definition of these
scenarios. Moreover, for this reason, the inputs and outputs of functions supporting
Bernoulli outcomes make no reference to the τk, and work instead directly in terms of the
pik. Finally, note that this problem also means that to determine A-, D-, or E-optimised
allocation ratios, a specific set of values for the pik must be assumed.
In this case, we should also ensure that δ1 ∈ (0, 1) and δ0 ∈ (−pi0, δ1), for the assumed
value of pi0, since pik ∈ [0, 1] for k ∈ {1, . . . , K}.
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Results
Support
The web application is freely available from https://mjgrayling.shinyapps.io/multiarm/.
The R code for the application can also be downloaded from
https://github.com/mjg211/multiarm. Furthermore, as noted earlier, the app is
built in to the package multiarm [27], as the function gui(), for ease-of-use without
internet access. The application has a simple interface, and has the capability to
• Determine the sample required in each arm in a specified multi-arm clinical trial
design scenario;
• Summarise and plot the operating characteristics of the identified design;
• Produce a report describing the chosen design scenario, the identified design, and a
summary of its operating characteristics.
Inputs
The outputs (i.e., the identified design and its operating characteristics) are determined
based upon the following set of user specified inputs (Figure 1)
1. The number of experimental treatment arms, K.
2. The chosen multiple comparison correction (e.g., Dunnett’s correction).
3. The significance level, α.
4. The type of power to control (e.g., the conjunctive power under HA).
5. The desired power, 1− β.
6. For Bernoulli distributed data, the control arm response rate pi0.
7. The interesting treatment effect, δ1.
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8. The uninteresting treatment effect, δ0.
9. For normally distributed data, the standard deviations, σ0, . . . , σK . These are allo-
cated by first selecting the type of standard deviations (e.g., that they are assumed
to be equal across all arms), and then the actual values for the parameters.
10. The allocation ratios (e.g., A-optimal).
11. For Bernoulli distributed data, when searching for optimal allocation ratios, the
response rates to assume in the search.
12. Whether the sample size in each arm should be required to be an integer;
13. Whether plots should be produced, and if so the plot quality.
Note that a Reset inputs button is provided to simplify returning the inputs to their
default values. Once the inputs have been specified as desired, the outputs can be gener-
ated by clicking the Update outputs button.
Example
Here, we demonstrate specification of the input parameters (Figure 1), and then subse-
quent output generation (Figures 2-4), for parameters motivated by a three-arm phase
II randomized controlled trial of treatments for myelodysplastic syndrome patients, de-
scribed in [38]. This trial compared, via a binary primary outcome, two experimental
treatments with conventional azacitidine treatment. The trial was designed with α = 0.15,
β = 0.2, δ1 = 0.15, and pi0 = 0.3. For simplicity, we assume that the familiar Dunnett
correction will be used, that δ0 = 0, and that allocation will be equal across the arms
(r1 = · · · = rK = 1). Finally, we assume it is the minimum marginal power that should
be controlled.
Each input widget in Figure 1 can be seen to have been allocated accordingly based
on the description above, whilst we have additionally elected to produce plots (of medium
quality), and to not require the arm-wise sample sizes to be integers. Note that in Figure
14
1 we can see that the input widgets are supported by help boxes that can be opened by
clicking on the small question marks beside them.
Figure 2 then depicts the output to the Design summary box once the user clicks on
Update outputs. Specifically, a summary of the chosen inputs and the identified design
is rendered. Furthermore, in Figure 3 we can see the tables that provide the various
statistical quantities under HG, HA, the LFCk, as well as the various treatment effect
scenarios that are considered for plot production.
Finally, in Figure 4 the plots discussed earlier are shown. Observe that horizontal and
vertical lines are added at the values α, 1−β, δ1, and δ0 respectively. Note that these plots
are outputted in a manner to allow the user to zoom in on a particular sub-component if
desired.
In all, Figures 2-4 provide a set of outputs with a variety of features that should
be anticipated given the chosen input parameters. Firstly, the specification that the
allocation to all arms should be equal means that n0 = · · · = nK . In addition, FWERI1
is equal to 0.15 under HG, and the minimum marginal power is 0.799, as is approximately
desired. Moreover, the specification that r1 = · · · = rK means that Pcon and Pdis are equal
for each of the LFCk, and P1 = P2.
Finally, as noted above, and as can be seen in Figure 1, a Generate report button is
provided that can produce a copy of the outputs in either PDF (.pdf), HTML (.html),
or Word (.docx) format. The user can also nominate a name for this file in the Report
filename input widget. This allows a record of designs to be stored, presented, and
compared to other designs if required.
Conclusions
A possible barrier to previous calls for increased use of multi-arm clinical trial designs is a
lack of available easy-to-access user-friendly software that facilitates associated sample size
calculations. For this reason, we have created an online web application that supports
multi-arm trial design determination for a wide selection of possible input parameters.
Its use requires no knowledge of statistical programming languages and is facilitated
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via a simple user interface. Furthermore, we have made the application available on the
internet, so that it is readily accessible, and have also made it freely available for download
for remote use without an internet connection. Like similar applications that have been
released recently for phase I clinical trial design [39, 40], we hope that the availability of
this application will assist with the design of future multi-arm studies.
Before we conclude, however, it is important to acknowledge the limitations of our
work. Firstly, MVN integration is utilised in all instances to determine the statistical
operating characteristics of potential multi-arm designs. This makes the execution time
for returning outputs with many possible input parameters fast. However, there is an
unavoidable complexity in certain multi-arm designs, which may make execution time
long. This is particularly true of scenarios with K ≥ 5. It can also be true of designs that
utilise the more complex step-wise MCCs. It is for this reason that the application places
an upper cap in the inputs of K = 5, and also returns a warning in scenarios for which a
lengthy execution time would be anticipated. Nonetheless, users may have to wait several
minutes in certain situations to identify their desired design.
Furthermore, it is crucial that all software for clinical trial design be validated. This
is challenging for multi-arm designs because of the aforementioned limited freely available
software for designing such studies. We compared the output of our application to that
of PASS [41], a validated software package, for a variety of supported input parameters,
but output for many possible inputs remained difficult to corroborate because of a lack
of equivalent available functionality. For this reason, we have carefully followed recom-
mended good-programming practices and perform all statistical calculations within the
application by calling functions from the R package multiarm, in which the code has been
modularised [27]. Furthermore, in this package we have created a function that simulates
multi-arm clinical trials using a given design. This allows us to perform an additional
check on our analytical computations. Specifically, we generated 1000 random combina-
tions of possible input parameters for trials assuming normally distributed outcomes, thus
covering an extremely wide range of supported design scenarios. The analytical operating
characteristics returned by the web application in the Operating characteristics summary
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boxes for HG, HA, and the LFCk were then compared to those based on trial simulation,
using 100,000 replicate simulations in each of the 1000 designs. Across all considered sce-
narios, the maximum absolute difference between the analytical and simulated operating
characteristics was just 5× 10−3, which is within what would be anticipated due to sim-
ulation error. Consequently, it does appear that our command is functioning as desired.
Code to replicate this work is available upon request from the corresponding author.
Finally, we note one primary possible avenue for future development of the web appli-
cation: numerous papers have now provided designs for adaptive multi-arm trials (e.g.,
[42, 43]), and software for their determination in certain settings [44, 45]. Given the evi-
dential increased interest in such designs [46], allowing for their determination would be
a valuable extension to our application.
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Figure 1: Design parameters box. The box in which input parameters are specified
is shown. The specific values that can be seen are those that correspond to the trial
described in [38].
23
Figure 2: Design summary box. The box in which a summary of the input parameters
and of the identified design is rendered is shown. The specific output that can be seen
corresponds to the inputs from Figure 1.
24
Figure 3: Operating characteristics summary. The boxes in which a summary of the
identified designs operating characteristics is produced is shown. The specific output that
can be seen corresponds to the inputs from Figure 1.
25
Figure 4: Operating characteristics plots. The boxes in which plots of the identified
designs operating characteristics are produced is shown. The specific output that can be
seen corresponds to the inputs from Figure 1.
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